Evidence map›Paper›PMID 41001021›Full record

ArticleFrontiers in oncology2025

Real-world treatment patterns and clinical outcomes among elderly patients with locoregionally advanced head and neck squamous cell carcinoma in the United States.

Dandan Zheng, Su Zhang, Behzad Bidadi, Nati Lerman, Yan Song, Rui Song, Jiayang Li, Anyu Zhu, Yuexin Tang, James Signorovitch and 2 more

Erratum issuedAbstract read
In one paragraph

Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors.

Dandan ZhengOutcomes Research, Merck & Co., Inc., Rahway, NJ, United States.
Su ZhangAnalysis Group, Inc., Boston, MA, United States.
Behzad BidadiOncology Late Stage Development, Merck & Co., Inc., Rahway, NJ, United States.
Nati LermanOncology Late Stage Development, Merck & Co., Inc., Rahway, NJ, United States.
Yan SongAnalysis Group, Inc., Boston, MA, United States.
Rui SongAnalysis Group, Inc., Boston, MA, United States.
Jiayang LiAnalysis Group, Inc., Boston, MA, United States.
Anyu ZhuAnalysis Group, Inc., Boston, MA, United States.
Yuexin TangOutcomes Research, Merck & Co., Inc., Rahway, NJ, United States.
James SignorovitchAnalysis Group, Inc., Boston, MA, United States.
Sanjay MerchantOutcomes Research, Merck & Co., Inc., Rahway, NJ, United States.
Glenn J HannaCenter for Head and Neck Oncology, Dana-Farber Cancer Institute, Boston, MA, United States.

Funding

NCI NIH HHS HHSN261201800009CNCI NIH HHS HHSN261201800009INCI NIH HHS HHSN261201800015CNCI NIH HHS HHSN261201800015INCI NIH HHS HHSN261201800032CNCI NIH HHS HHSN261201800032I
6 · The paper itself

Abstract

Introduction: Multimodal therapy, including resection followed by adjuvant radiotherapy (RT) ± systemic therapy (ST) or definitive RT ± ST, is typically recommended for patients with locoregionally advanced head and neck squamous cell carcinoma (LA HNSCC) treated with curative intent. We assessed the real-world use of various treatment modalities and associated survival outcomes among elderly patients with LA HNSCC who received surgical or non-surgical primary treatment. Methods: Linked SEER-Medicare data were used in this retrospective cohort study. Patients with newly diagnosed stage III-IVB LA HNSCC (larynx, hypopharynx, oral cavity, or oropharynx) from 2007-2019 who received primary treatment within 4 months after initial diagnosis were included. Real-world event-free survival (rwEFS) and overall survival (rwOS) from the index date (primary treatment initiation date) were described using Kaplan-Meier estimates. The correlation between rwEFS and rwOS was investigated by normal scores rank. Landmark analysis was conducted using Cox proportional hazards models to compare rwOS between patients with versus without recurrence in the first year after primary treatment initiation. Results: Of 2180 patients meeting the selection criteria, 626 and 1554 were categorized into the resected and unresected cohorts, respectively (median follow-up: 20.8 and 22.6 months). Overall, the mean age at initial diagnosis was 74.3 years, 65.9% were male, and 81.7% were White. More than half (56.3%) of the patients with resected tumors received RT ± ST post-surgery while nearly two-thirds (64.9%) of those with unresected tumors received definitive RT+ST. The resected cohort had a median rwEFS of 7.8 (95% confidence interval [CI]: 6.4, 8.7) months and a median rwOS of 31.4 (95% CI: 25.2, 40.1) months. The unresected cohort had a median rwEFS of 10.0 (95% CI: 9.4, 10.9) months and a median rwOS of 32.4 (95% CI: 28.5, 36.7) months. There was a significant positive correlation between rwEFS and rwOS for both the resected ( Conclusion: In elderly patients with LA HNSCC, surgery followed by RT and definitive RT+ST were the most common treatment modalities in the resected and unresected cohorts, respectively. The suboptimal real-world survival of both groups highlights the significant unmet need for more effective therapies. The positive associations between rwEFS and rwOS in both the resected and unresected cohorts support EFS as a predictor of OS when OS data are immature in LA HNSCC.

Indexed as

event-free survivalhead and neck squamous cell carcinomalocoregionally advancedmedicareoverall survivalreal worldtreatment patterns

Identifiers

PMID41001021
PMCPMC12457382

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.